Pluristem Therapeutics is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment.
Evogene
Post IPO Equity • Rehovot, Israel
Compugen
Post IPO Equity • Holon, Israel
IsoPlexis
Post IPO Equity • Branford, United States
Evofem Biosciences
Post IPO Equity • San Diego, United States
Summit Therapeutics
Post IPO Equity • Cambridge, United States
Protagonist Therapeutics
Post IPO Equity • Newark, United States
OncoSec
Post IPO Equity • San Diego, United States
Otonomy
Post IPO Equity • San Diego, United States
Sutro Biopharma
Post IPO Equity • South San Francisco, United States
Abeona Therapeutics
Post IPO Equity • Dallas, United States
Sorrento Therapeutics
Post IPO Equity • San Diego, United States
Cara Therapeutics
Post IPO Equity • Stamford, United States